Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2

CP O'Kane, JCO Avalon, JL Lacoste… - … : The Journal of …, 2022 - Wiley Online Library
Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …
被引用次数：17 相关文章
[PDF] researchgate.net

[PDF][PDF] Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI≥ 50 kg/m2

CP O'Kane, JCO Avalon, JL Lacoste, W Fang… - …, 2022 - researchgate.net
Background: Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non-valvular atrial fibrillation (NVAF) and commonly in patients …

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2.

CP O'Kane, JCO Avalon, JL Lacoste, W Fang… - …, 2021 - europepmc.org
Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non-valvular atrial fibrillation (NVAF) and commonly in patients …

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI≥ 50 kg/m2

CP O'Kane, JCO Avalon, JL Lacoste… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non-valvular atrial fibrillation (NVAF) and commonly in patients …